Abstract Library

#2014 Imaging of Advanced Medullary Thyroid Carcinoma with the CCK-2 Receptor Agonist 177Lu-PP-F11N – Preliminary Proof of the Principle within the “Lumed” Study

Introduction: Despite the introduction of new molecular targeted therapies, there is still an unmet need for an effective systemic therapy for advanced medullary thyroid carcinoma (MTC). Targeting the cholecystokinine-2 (CCK-2) receptor with radiolabeled gastrin analogues is a potential approach for radionuclide therapy of MTC.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Rottenburger C, Nicolas G, McDougall L, Kaul F, Christ E,

Keywords: Medullary thyroid carcinoma, cholecystokinine-2 receptor, radionuclide therapy, theranostics,

#1057 Localisation of Insulinoma and Beta-Cells: Comparison of Glucagon-Like Peptide-1 Receptor (GLP1-R) SPECT/CT, PET/CT and MRI. Preliminary Results of a Prospective Clinical Study.

Introduction: SPECT/CT imaging with GLP1-R specific radiotracers like 111In-DOTA-exendin-4 have already proved to be a useful tool for the preoperative localisation of insulinomas. PET/CT has several advantages over SPECT/CT: lower radiation exposure, less time consumption and higher spatial resolution.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Rottenburger C, Antwi K, Heye T, Fani M, Nicolas G,

Keywords: Insulinoma, Nesidioblastosis, Glucagon-like Peptide-1 Receptor, PET/CT, SPECT/CT,